Accessibility Menu
Neumora Therapeutics logo

Neumora Therapeutics(NASDAQ) NMRA

Market Cap$308.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-90%
5 YearN/A
1 Year+2%
1 Month+1%
$1.50
-8.54%
-0.14Today
Neumora Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.642026-08-19
Neumora Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.09%USD 1.712026-08-12
1 month+0.61%USD 1.632026-07-20
3 month-11.35%USD 1.852026-05-21
Year to date-8.38%USD 1.792025-12-31
1 year+1.86%USD 1.612025-08-19
Since inception-89.91%USD 16.252023-09-15

Neumora Therapeutics Financials at a Glance

Market Cap

$308.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$212.75M

EPS (TTM)

-$1.23

P/E Ratio

-1.33

Dividend

$0.00

Beta (Volatility)

1.53 (High)

Price

$1.50

Volume

671,253.046

Open

$1.61

Previous Close

$1.64

Daily Range

$1.49 - $1.63

52-Week Range

$0.83 - $3.65

Estimated Earnings Date

Nov 5, 2026

NMRA News

Foolcom-Featured.png

Neumora (NMRA) Q2 Loss Improves 10%

Motley Fool Markets TeamAug 6, 2025
Nurse tending patient in intensive care

Why Shares of Neumora Therapeutics Slumped This Week

James HalleySep 21, 2023

NMRA: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neumora Therapeutics

Neumora Therapeutics, Inc. makes medicines for brain and mood disorders. These treatments help people with depression and Alzheimer's disease. The company tests these drugs in clinical trials.

The Brain Health Pipeline

  • Navacaprant (NMRA-140): A daily oral pill for major depressive disorder that concluded Phase 3 clinical trials in 2026.
  • NMRA-511: A drug candidate targeting agitation in patients with Alzheimer's disease; completed its Phase 1b study in 2025.
  • NMRA-898: A potential treatment for schizophrenia that targets specific acetylcholine receptors in the brain to improve signaling.
  • NMRA-215: An oral medicine designed to treat obesity and heart health risks by inhibiting specific inflammatory proteins.

Recent Strategic Steps

  • Completed its initial public offering in Sept. 2023, generating $226.5 million in net proceeds.
  • Obtained a $125 million loan facility in May 2025 to provide operating capital for research.
  • Acquired clinical candidates and license agreements through a merger with BlackThorn and a partnership with Vanderbilt.
  • Terminated a multiyear research and collaboration agreement with Amgen in Sept. 2024.

How Neumora Finds Patients

Neumora uses a precision neuroscience approach to match its drug candidates with specific patient groups based on biological data. This strategy aims to improve the success rate of clinical trials by focusing on patients most likely to respond to the treatment.

Financials at a Glance

  • Net loss was $43.1 million for the three-month period ended June 30, 2026.
  • Research and development expenses were $29.3 million in the second quarter of 2026, down 24% year over year.
  • Cash and cash equivalents totaled $116.8 million as of June 30, 2026.
  • Market capitalization reached $314.8 million in the second quarter of 2026, up 165.5% year over year.

Bottom Line

Neumora has evolved into a clinical-stage organization with multiple drug candidates targeting underserved brain health markets. The company continues to prioritize its pipeline while navigating the financial requirements of medical research.

AI Generated • Aug 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

96

CEO

Paul L. Berns

Website

www.neumoratx.com

Headquarters

Watertown, MA 02472, US

NMRA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-242.28%

Return on Capital

-231.11%

Return on Assets

-169.86%

Earnings Yield

-75.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$308.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

187.90M

Volume

671.25K

Avg. Volume

1.94M

Financials (TTM)

Gross Profit

-$5.01M

Operating Income

-$211.23M

EBITDA

-$207.14M

Operating Cash Flow

-$180.52M

Capital Expenditure

$0.00

Free Cash Flow

-$180.52M

Cash & ST Invst.

$116.83M

Total Debt

$340.00K

Neumora Therapeutics Performance Analysis

Neumora Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Neumora Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Neumora Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.86-44.8%
20232023-12-31USD -1.4972.4%
20242024-12-31USD -1.533.0%
20252025-12-31USD -1.45-5.2%
Neumora Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.1%
Q42025-12-31N/A
Q12026-03-3114.3%
Q22026-06-3023.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$308.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.35M

N/A

Employees

92

N/A

Net Income

-$43.08M

+18.3%

EBITDA

-$42.18M

+19.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$116.83M

-46.3%

Total Debt

$340.00K

-98.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$41.00K

-99.8%

Short Term Debt

$299.00K

+74.9%

Return on Assets

-1.70%

N/A

Return on Invested Capital

-2.17%

N/A

Free Cash Flow

-$39.53M

+24.6%

Operating Cash Flow

-$39.53M

+24.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FULCFulcrum Therapeutics, Inc.
$3.82-2.30%
BCYCBicycle Therapeutics plc
$4.10-1.09%
PRTAProthena Corporation plc
$8.80-5.33%
ADCTADC Therapeutics S.A.
$0.97-6.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.19+0.06%
SPCXSpace Exploration Technologies
$130.74-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.82-0.04%

Questions About NMRA

What is the current price of Neumora Therapeutics?

Neumora Therapeutics is trading at $1.50 per share.

What is the 52-week range for Neumora Therapeutics?

Over the past 52 weeks, Neumora Therapeutics has traded between $0.83 and $3.65.

How much debt does Neumora Therapeutics have?

As of the most recent reporting period, Neumora Therapeutics reported total debt of $53.25M.

How much cash does Neumora Therapeutics have on hand?

Neumora Therapeutics reported $116.83M in cash and cash equivalents in its most recent financial results.

What is Neumora Therapeutics’s dividend yield?

Neumora Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services